[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"epiretinal-membrane\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:epiretinal-membrane":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,49,73,103,129,152,187,214,243],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100645379","cirrus-2023-1-clinical-clin-assessment-of-pathfinder-10-on-the-cirrus-6000-and-the-cirrus-5000-100645379",false,"NCT07680244","(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000","Inclusion Criteria:\n\n1. Able and willing to make the required study visits.\n2. Able and willing to give written informed consent and follow study instructions.\n3. Able and willing to complete ophthalmic imaging.\n4. Adults 18 years of age or older.\n\nThe subject population will be comprised of two groups (all categories below pertain to the central 6x6 mm macula area):\n\nGroup A\n\n1\\. Subjects with absence of macular abnormalities Group B\n\n1. Subjects with Disruption of the vitreoretinal interface (VRI)\n2. Subjects with Intraretinal hyporeflective space (IRHS)\n3. Subjects with Subretinal hyporeflective space (SRHS)\n4. Subjects with IS\u002FOS (Ellipsoid Zone) disruption\n5. Subjects with Retinal Pigment Epithelium (RPE) elevation\n6. Subjects with Retinal Pigment Epithelium (RPE) atrophy\n7. Other abnormalities\n\nExclusion Criteria:\n\n1. Inability to undergo the required tests.\n2. Unable to give consent or follow study instructions.\n3. Inability to fixate that precludes obtaining acceptable macula scans in the study eye.\n4. Visudyne (verteporfin) injection within the last 48 hours in the study eye.\n5. Pilocarpine or Vuity use within the last 24 hours in the study eye.\n6. Dense media opacity precluding adequate visualization of the retina in the study eye.\n7. Vitreous floaters that preclude obtaining acceptable scans in the study eye.",true,"ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.",[26,27,28,29,30,31,32,33,34,35],"Epiretinal Membrane","Dry Age Related Macular Degeneration","Macular Abnormalities","Retina Disease","Vitreoretinal Abnormality","Intraretinal Hyporeflective Space","Subretinal Hyporeflective Space","IS\u002FOS (Ellipsoid Zone) Disruption","Retinal Pigment Epithelium (RPE) Elevation","Retinal Pigment Epithelium (RPE) Atrophy","RECRUITING","2026-06-29",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":40},"2025-05-23",{"date":44,"type":20},"2026-08",{"name":46,"class":47},"Carl Zeiss Meditec-Dublin CoCe","INDUSTRY",6,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100450438","randomized-trial-comparing-immediate-vs-deferred-surgery-for-symptomatic-erm-100450438","NCT05145491","Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM","Randomized Trial Comparing Immediate Versus Deferred Surgery for Symptomatic Epiretinal Membranes","Protocol AM","Key Inclusion Criteria:\n\n* Age ≥ 45 years\n* E-ETDRS visual acuity 20\u002F40 or better (≥69 letters)\n\n  o ERM must be thought to be the primary cause of vision loss\n* ERM meeting the following criteria, according to the investigator\n\n  * ERM is not secondary to another condition\n  * Symptoms of visual loss and\u002For distortion (in the opinion of the investigator, the ERM is contributing to the participant's symptoms); either new or worsening in the past 24 months\n  * Epiretinal membrane involving or altering the central 3 mm of the macula on OCT\n  * Distortion within the central subfield due to ERM on OCT\n* Immediate vitrectomy not required (investigator and participant are willing to wait at least 4 weeks to see if vision remains stable without having to proceed to vitrectomy)\n* No known medical problems that will be a contraindication to surgery\n\nKey Exclusion Criteria:\n\n* History of retinal vascular disease\n* History of vitreous hemorrhage if vitreous hemorrhage is thought to have caused the ERM\n\n  o History of vitreous hemorrhage is permitted provided the vitreous hemorrhage did not cause the ERM in the investigator's opinion\n* History of inflammatory disease unless mild and completely resolved at least one year prior to randomization\n* History of diabetic macular edema (DME), retinal vein occlusion (RVO), or uveitis (except mild uveitis that resolved \\>1 year prior to randomization)\n* Prior intraocular surgery (except uncomplicated cataract extraction)\n* Cataract extraction within prior 3 months\n* Laser or cryosurgical retinopexy within one month of randomization\n* Pneumatic retinopexy within one year of randomization\n* Current untreated retinal tear or detachment\n\n  o A previously treated retinal tear with up to one disc diameter radius of subretinal fluid is permitted\n* Macular hole\n* Degenerative lamellar macular hole\n\n  o ERM foveoschisis (\"tractional\" lamellar hole) is permitted\n* Vitreomacular traction within 1,500 microns of foveal center\n* Central serous chorioretinopathy\n* Nonproliferative diabetic retinopathy or worse (DR severity \\>20)","50 Years",{"count":19,"type":20},[23],"Vitrectomy to remove an epiretinal membrane (ERM) is one of the most common procedures performed by retinal surgeons. Patients who present with significant macular changes on optical coherence tomography (OCT) but relatively good vision are often advised to defer surgery until vision declines to 20\u002F40 or worse. However, it is unknown if delaying surgery, which allows the foveal architecture to remain compromised and potentially to deteriorate, results in worse visual acuity outcomes than if surgery is performed earlier. In addition, there is a need to better understand predictors of outcomes when surgery is performed and predictors of progression when surgery is deferred. Finally, one of the most common presenting symptoms from an ERM is distortion or metamorphopsia. There are several objective measures of metamorphopsia but none have ever been employed to evaluate ERMs in a randomized clinical trial (RCT) and their usefulness is unknown. The purposes of this study are to better understand the optimal timing of surgery to produce the best visual result, to better understand predictors of outcomes in those who undergo surgery and predictors of progression in those whose are observed, and to better characterize and evaluate the usefulness of metamorphopsia and reading speed measures.",[26],"2026-06-12",{"date":64,"type":40},"2026-06-15",{"date":66,"type":40},"2022-02-22",{"date":68,"type":20},"2026-12-31",{"name":70,"class":71},"Jaeb Center for Health Research","OTHER",47,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":80,"targetDuration":82,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100615388","retinal-clinical-assessment-with-ai-derived-quantitative-information-100615388","NCT07291960","Retinal Clinical Assessment With AI-derived Quantitative Information","AI-derived Retinal Quantification Versus Routine Clinical Interpretation in Ophthalmic Assessment: a Randomized Controlled Trial","Inclusion Criteria:\n\nClinician Participants (Report Writers)\n\n1. Board-certified ophthalmologists or ophthalmology trainees (registrars or fellows) with clinical experience in interpreting fundus images.\n2. Capable of independently completing retinal clinical reports based on fundus photography.\n3. Willing and able to participate in the study tasks (report writing) under assigned study conditions.\n4. Able to provide informed consent.\n\nExpert Evaluators (Outcome Assessors)\n\n1. Senior ophthalmologists with at least 5 years of post-certification clinical experience.\n2. Not involved in the report-writing stage of the study.\n3. Willing to evaluate de-identified reports across predefined quality dimensions.\n4. Able to provide informed consent.\n\nFundus Images (Data Inputs)\n\n1. Retinal fundus photographs of sufficient quality for clinical interpretation.\n2. Images representing a range of common retinal findings (normal or abnormal).\n3. Previously collected, de-identified images with no patient-identifiable information.\n\nExclusion Criteria:\n\nClinician Participants\n\n1. Lack of experience in interpreting fundus images (e.g., interns, medical students).\n2. Prior involvement in the development, training, or validation of the AI system being tested.\n3. Inability to complete reporting tasks due to time constraints or technical limitations.\n4. Any condition that may interfere with ability to perform study tasks (e.g., prolonged absence).\n\nExpert Evaluators\n\n1. Participation in the intervention or control reporting arms.\n2. Prior exposure to or involvement in development of the AI system.\n3. Any conflict of interest affecting impartiality of report quality evaluation.\n\nFundus Images\n\n1. Poor-quality images with insufficient clarity for interpretation.\n2. Images containing artifacts or cropping that prevent accurate segmentation or assessment.\n3. Images with any remaining patient identifiers (excluded to maintain confidentiality).",{"count":81,"type":20},29,"21 Days","OBSERVATIONAL","This randomized controlled trial evaluates whether providing clinicians with AI-derived quantitative retinal information improves the quality and efficiency of retinal clinical assessment. Participating ophthalmologists and ophthalmology trainees will be randomly assigned to one of two groups. The intervention group will write clinical reports with access to automated quantitative measurements generated from fundus image analysis, including multiple retinal structural and vascular biomarkers. The control group will complete the same reporting tasks using only the original fundus images without AI-generated quantitative information.\n\nAll reports produced by both groups will be de-identified and independently evaluated by a separate panel of senior ophthalmologists who are blinded to group allocation. The expert evaluators will assess report accuracy, completeness, clarity, and overall clinical quality using predefined scoring criteria. The study aims to determine whether access to quantitative retinal biomarkers enhances clinicians' reporting performance and reduces reporting time during retinal assessment tasks.",[86,87,88,89,90,91,26,92],"no Obvious Abnormalities","Diabetic Retinopathy (DR)","AMD","Cup-to-disc Ratio Bigger Than 0.5","Pathological Myopia","Macular Hole","Retinal Vein Occlusion (RVO)","NOT_YET_RECRUITING","2026-04-28",{"date":96,"type":40},"2026-04-29",{"date":98,"type":20},"2026-04-15",{"date":100,"type":20},"2026-05-15",{"name":102,"class":71},"Beijing Tongren Hospital",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100571398","functional-iol-implantation-in-patients-with-epiretinal-membrane-100571398","NCT06719739","Functional IOL Implantation in Patients With Epiretinal Membrane","Clinical Outcomes in Cataract Patients With Macular Epiretinal Membrane After Implantation of Functional Intraocular Lenses","Inclusion Criteria:\n\n* Requirement for cataract extraction\n* Age \\> 40 years\n* Axial length in 21mm to 25mm\n* ERM\n\nExclusion Criteria:\n\n* Residual corneal astigmatism \\> 1.0 D\n* Amblyopia\n* Previous ocular surgery\n* Other ocular pathologies apart from mERM, such as diabetic retinopathy, macular degeneration, glaucoma with field defects\n* Requirements for further ocular surgery (other than Nd:YAG capsulotomy) or retinal laser treatments during the study","20 Years","90 Years",{"count":113,"type":20},90,[23],"We have designed this prospective study to evaluate macular involvement and epiretinal membrane (ERM) grading by OCT in eyes with ERM and to compare clinical outcomes after implantation of Enhance IOL with standard monofocal IOL in eyes with ERM grading preoperatively, aiming to find out whether functional IOL is benefit for patients with ERM.",[117,118,26],"Cataract","Intraocular Lens Complication","2026-04-02",{"date":121,"type":40},"2026-04-08",{"date":123,"type":40},"2024-09-21",{"date":125,"type":20},"2026-09-21",{"name":127,"class":71},"Eye & ENT Hospital of Fudan University",2,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":138,"studyType":83,"phases":4,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100611535","epiretinal-membrane-in-patients-with-dr-100611535","NCT07241845","Epiretinal Membrane in Patients With DR.","Epiretinal Membrane in Patients With Diabetic Retinopathy.","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Patients with ERM confirmed by OCT images.\n* Patients with DM with varying severity of diabetic retinopathy.\n\nExclusion Criteria:\n\n* • History of previous eye trauma or surgery other than uneventful cataract surgery, uveitis, history of retinal detachment, media opacity impairing the quality OCT images, high myopia, macular or retinal diseases disease affecting the visual acuity other than diabetic retinopathy, e.g. macular hole, retinitis pigmentosa, AMD, CRVO.",{"count":137,"type":20},225,"1 Year","To report the prevalence of ERM among patients with diabetic retinopathy, and the possible associated risk factors.",[26],[142],"oct","2025-11-17",{"date":145,"type":40},"2025-11-21",{"date":147,"type":20},"2026-01",{"date":149,"type":20},"2028-10",{"name":151,"class":71},"Assiut University",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":15,"sex":16,"minAge":160,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":163,"conditions":164,"keywords":173,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":186},"100340496","intraoperative-oct-guidance-of-intraocular-surgery-ii-100340496","NCT03713268","Intraoperative OCT Guidance of Intraocular Surgery II","Intraoperative OCT Guidance of Intraocular Surger","MIOCT","Inclusion Criteria:\n\n1. Healthy controls: Healthy eyes without known disease: refractive error including myopia and non-significant cataract is allowed. For selected testing pseudophakia is allowed.\n2. Surgeons as research subjects: Adult (≥18 years old)\n3. Surgical patients (vitreoretinal surgery): Patients undergoing examination under anesthesia or surgery for vitreoretinal diseases\n4. Surgical patients (anterior segment surgery-glaucoma, ocular surface or strabismus requiring extraocular muscle surgery): Include both adults and children. Patient undergoing primary, elective minimally invasive glaucoma surgery, ocular surface surgery, or strabismus surgery.\n\nExclusion Criteria:\n\n1. Healthy controls: Any ocular disease that restricts the ability to perform OCT scanning. Conflict of interest with investigators\u002Fstudy personnel, e.g. a student in the lab of an investigator.\n2. Surgeons as research subjects: no specific exclusion criteria.\n3. Surgical patients (vitreoretinal surgery): Neonates (\\\u003C 4 weeks of age) and patients with any ocular disease that restricts the ability to perform OCT scanning.\n4. Surgical patients (anterior segment surgery-corneal and cataract diseases): Pediatric patients: The cornea and cataract surgery studies will be restricted to adults (≥ 18 years). Children do not have cataract surgery typically by residents and therefore would not fit our study design. Similarly pediatric corneal transplants are very rare.","4 Weeks",{"count":162,"type":20},262,"The overall five-year goals of the project are to develop novel technology to provide actionable new information through provision of live volumetric imaging during surgery, improving surgical practice and outcomes. The investigators believe this technology will enable novel ophthalmic and other microsurgeries not possible due to current limitations in surgical visualization.",[165,26,166,167,168,169,117,170,171,172],"Macular Holes","Diabetic Retinopathy","Retinal Detachment","Retinal Disease","Preretinal Fibrosis","Ocular Tumor","Strabismus","Healthy",[174,158,175,176],"Microscope Integrated optical coherence tomography","OCT Angiography","OCTA","2025-10-02",{"date":179,"type":40},"2025-10-06",{"date":181,"type":40},"2018-09-30",{"date":183,"type":20},"2027-05-31",{"name":185,"class":71},"Duke University",1,{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":197,"conditions":198,"keywords":201,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":186},"100241590","discover-study-microscope-integrated-intraoperative-oct-study-100241590","NCT02423213","DISCOVER Study: Microscope-integrated Intraoperative OCT Study","Determination of Feasibility of Intraoperative Spectral Domain Microscope Combined\u002FIntegrated OCT Visualization During En Face Retinal and Ophthalmic Surgery: DISCOVER Study","DISCOVER","Inclusion Criteria:\n\n* The study population includes any patient requiring ophthalmic surgery\n\nExclusion Criteria:\n\n* Under the age of 18 years.\n* Cognitive\u002FMentally impaired or unable to provide consent",{"count":196,"type":20},3000,"Optical coherence tomography (OCT )provides high resolution information regarding the anatomic structure of the tissues of the eye in a cross-sectional and 3 dimensional view. Much of this information is not able to be visualized by a clinician. Utilizing this information during surgery will allow for the ophthalmic surgeons to better understand how surgical procedures impact the anatomic structure of the eye.\n\nIn this study an OCT device that has been built into the microscope (rather than mounted on the side or held in the surgeon's hand) and will be utilized to take images at various milestones during surgery to assess feasibility and potential utility of this technology. Since it is built into the microscope, there are potential significant advantages over a separate system including increased efficiency, improved working distance, and the ability to visualize tissue-instrument interactions.",[199,200,91,26,167],"Retinal Diseases","Fuchs Endothelial Dystrophy",[202,203,204],"OCT","image-guided surgery","ophthalmic surgery","2025-06-23",{"date":207,"type":40},"2025-06-26",{"date":209,"type":4},"2014-01",{"date":211,"type":20},"2027-01",{"name":213,"class":71},"The Cleveland Clinic",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":21,"phases":224,"briefSummary":225,"conditions":226,"keywords":229,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":186},"100594473","minimal-vitrectomy-surgery-for-epiretinal-membrane-100594473","NCT07019896","Minimal Vitrectomy Surgery for Epiretinal Membrane","Minimal Vitrectomy Surgery (MVS) Versus Conventional Vitrectomy for the Treatment of Idiopathic Epiretinal Membrane: A Multicenter Randomized Controlled Trial","MVS-ERM","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Diagnosis of idiopathic epiretinal membrane (ERM) confirmed by clinical examination and OCT imaging.\n3. Clear ocular media allowing adequate fundus imaging.\n4. Phakic eye.\n5. Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n1. Prior cataract surgery or advanced cataract requiring combined surgery. Co-existing retinal diseases (e.g., diabetic retinopathy, retinal detachment, retinal vein occlusion).\n2. Systemic conditions preventing safe surgery or follow-up.\n3. History of prior ocular or periocular corticosteroid use, including intraocular injection, periocular injection, or long-term topical corticosteroid eye drops.",{"count":223,"type":20},140,[23],"This multicenter randomized controlled trial evaluates Minimal Vitrectomy Surgery (MVS) versus conventional vitrectomy for idiopathic epiretinal membrane (ERM). The primary endpoints include visual acuity improvement and cataract progression after 12 months. MVS aims to minimize vitreous removal while ensuring complete membrane removal through adaptive limited vitrectomy.",[26,227,228],"Macular Edema (ME)","Nuclear Cataract",[230,231,232,233],"Idiopathic Epiretinal Membrane (ERM)","Minimal Vitrectomy Surgery (MVS)","Nonvitrectomizing Vitreous Surgery (NVS)","pars plana Vitrectomy (PPV)","2025-06-05",{"date":236,"type":40},"2025-06-13",{"date":238,"type":40},"2024-12-01",{"date":240,"type":20},"2026-11-30",{"name":242,"class":71},"Peking Union Medical College Hospital",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":16,"minAge":250,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":21,"phases":253,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":186},"100557319","phase-4-comparison-of-efficacy-between-ilm-forceps-100557319","NCT06536569","Comparison of Efficacy Between ILM Forceps","A Comparison of the Efficacy of 25g Grieshaber Sharkskin ILM Forceps With Reflex Handle vs Standard 25g Grieshaber ILM Forceps for Internal Limiting Membrane Peeling","Inclusion Criteria:\n\n• 19y and older patients with symptomatic ERM (grade 2-3) or Macular hole (non flap-requiring) for elective ILM peeling surgery.\n\nExclusion Criteria:\n\n* Co-morbid diabetic retinopathy of any grade.\n* Neovascular AMD.\n* Previous vitrectomy.\n* Previous retinal detachment treated with scleral buckle or pneumatic retinopexy.\n* Uncontrolled glaucoma or previous glaucoma surgery.\n* Combined phacovitrectomy.\n* Macula holes with severity requiring flap.","19 Years",{"count":252,"type":20},56,[254],"PHASE4","This study is a Single center, prospective, observational, multi surgeon randomized controlled trial. Subjects will be assessed pre-operatively, operatively and at 1 month postoperatively. Clinical evaluations will include measurement of visual acuity and optical coherence tomography (OCT).",[165,26],"2025-03-25",{"date":259,"type":40},"2025-03-30",{"date":261,"type":20},"2025-07-01",{"date":263,"type":20},"2026-01-01",{"name":265,"class":71},"University of British Columbia"]